纳米粒子在乳腺癌诊断和治疗中的应用进展

doi:10.11904/j.issn.1002-3070.2025.02.011

Abstract

Abstract: Breast cancer is one of the most common cancers among women in the world,and the continuous progress of its diagnosis and treatment technology is crucial to improve the patient survival rates and quality of life.In recent years,the rapid development of nanotechnology has provided a new strategy for the diagnosis and treatment of breast cancer.This article summarizes the application progress of nanoparticles in the diagnosis and treatment of breast cancer,covering breast cancer imaging,drug delivery,gene therapy,and immunotherapy,and discusses the future development trend.

Key words: Breast cancer, Cancer treatment, Clinical applications, Nanotechnology

CLC Number:

R737.9

WANG Shuai, LI Qiqing, LI Rui, XU Tiefeng. Advances in the application of nanoparticles in the diagnosis and treatment of breast cancer[J]. Journal of Practical Oncology, 2025, 39(2): 151-156.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2025.02.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2025/V39/I2/151

References

1 Luo W,Ali YF,Liu C,et al.Particle therapy for breast cancer:benefits and challenges[J].Front Oncol,2021,11:662826.
2 Prat A,Pineda E,Adamo B,et al.Clinical implications of the intrinsic molecular subtypes of breast cancer[J].Breast,2015,24:26-35.
3 Majeed W,Aslam B,Javed I,et al.Breast cancer:major risk factors and recent developments in treatment[J].Asian Pac J Cancer Prev,2014,15(8):3353-3358.
4 Kashyap A,Kumari M,Singh A,et al.Current development of theragnostic nanoparticles for women's cancer treatment[J].Biomed Mater,2024,19(4):042001.
5 Cheang MCU,Voduc D,Bajdik C,et al.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J].Clin Cancer Res,2008,14(5):1368-1376.
6 Leidy J,Khan A,Kandil D.Basal-like breast cancer:update on clinicopathologic,immunohistochemical,and molecular features[J].Arch Pathol Lab Med,2014,138(1):37-43.
7 Ashrafizadeh M,Delfi M,Hashemi F,et al.Biomedical application of chitosan-based nanoscale delivery systems:Potential usefulness in siRNA delivery for cancer therapy[J].Carbohydr Polym,2021,260:117809.
8 Juan AS,Montembault A,Gillet D.Degradation of chitosan-based materials after different sterilization treatments.IOP Conf Ser[J].Mater Sci Eng C Mater Biol Appl,2012,31(1):1-5.
9 Chiu CF,Fu RH,Hsu S,et al.Delivery capacity and anticancer ability of the berberine-loaded gold nanoparticles to promote the apoptosis effect in breast cancer[J].Cancers,2021,13(21):5317.
10 Park SY,Chae SY,Park JO,et al.Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells[J].Oncol Rep,2016,35(6):3248-3256.
11 Sadhukhan P,Kundu M,Chatterjee S,et al.Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy[J].Mater Sci Eng C,2019,100:129-140.
12 Hussain Y,Mirzaei S,Ashrafizadeh M,et al.Quercetin and its nano-scale delivery systems in prostate cancer therapy:paving the way for cancer elimination and reversing chemoresistance[J].Cancers,2021,13(7):1602.
13 Salehiabar M,Ghaffarlou M,Mohammadi A,et al.Targeted CuFe2O4 hybrid nanoradiosensitizers for synchronous chemoradiotherapy[J].J Control Release,2023,353:850-863.
14 Niu S,Zhang X,Williams GR,et al.Hollow mesoporous silica nanoparticles gated by chitosan-copper sulfide composites as theranostic agents for the treatment of breast cancer[J].Acta Biomater,2021,126:408-420.
15 Wang J,Wang Y,Liu Q,et al.Rational design of multifunctional dendritic mesoporous silica nanoparticles to load curcumin and enhance efficacy for breast cancer therapy[J].ACS Appl Mater Interfaces,2016,8(40):26511-26523.
16 Li N,Wang Z,Zhang Y,et al.Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy[J].Artif Cells Nanomed Biotechnol,2018,46(2):921-935.
17 Aghapour F,Moghadamnia AA,Nicolini A,et al.Quercetin conjugated with silica nanoparticles inhibits tumor growth in MCF-7 breast cancer cell lines[J].Biochem Biophys Res Commun,2018,500(4):860-865.
18 Zang X,Cheng M,Zhang X,et al.Quercetin nanoformulations:a promising strategy for tumor therapy[J].Food Funct,2021,12(15):6664-6681.
19 Kumari M,Sharma N,Manchanda R,et al.PGMD/curcumin nanoparticles for the treatment of breast cancer[J].Sci Rep,2021,11(1):3824.
20 Abdel-Hakeem MA,Mongy S,Hassan B,et al.Curcumin loaded chitosan-protamine nanoparticles revealed antitumor activity via suppression of NF-κB,proinflammatory cytokines and Bcl-2 gene expression in the breast cancer cells[J].J Pharm Sci,2021,110(9):3298-3305.
21 de Oliveira Pedro R,Hoffmann S,Pereira S,et al.Self-assembled amphiphilic chitosan nanoparticles for quercetin delivery to breast cancer cells[J].Eur J Pharm Biopharm,2018,131:203-210.
22 Chiu CF,Fu RH,Hsu S,et al.Delivery capacity and anticancer ability of the berberine-loaded gold nanoparticles to promote the apoptosis effect in breast cancer[J].Cancers,2021,13(21):5317.
23 Park SY,Chae SY,Park JO,et al.Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells[J].Oncol Rep,2016,35(6):3248-3256.
24 Ghanbari N,Salehi Z,Khodadadi AA,et al.Glucosamine-conjugated graphene quantum dots as versatile and pH-sensitive nanocarriers for enhanced delivery of curcumin targeting to breast cancer[J].Mater Sci Eng C Mater Biol Appl,2021,121:111809.
25 Hatamie S,Akhavan O,Sadrnezhaad SK,et al.Curcumin-reduced graphene oxide sheets and their effects on human breast cancer cells[J].Mater Sci Eng C Mater Biol Appl,2015,55:482-489.
26 Hai L,He D,He X,et al.Facile fabrication of a resveratrol loaded phospholipid@ reduced graphene oxide nanoassembly for targeted and near-infrared laser-triggered chemo/ photothermal synergistic therapy of cancer in vivo[J].J Mater Chem B,2017,5(29):5783-5792.
27 Nasrollahi F,Koh YR,Chen P,et al.Targeting graphene quantum dots to epidermal growth factor receptor for delivery of cisplatin and cellular imaging[J].Mater Sci Eng C Mater Biol Appl,2019,94:247-257.
28 Ghamkhari A,Abbaspour-Ravasjani S,Talebi M,et al.Development of a graphene oxide-poly lactide nanocomposite as a smart drug delivery system[J].Int J Biol Macromol,2021,169:521-531.
29 Astani S,Salehi R,Massoumi B,et al.Co-delivery of cisplatin and doxorubicin by carboxylic acid functionalized poly(hydroxyethyl methacrylate)/reduced graphene nanocomposite for combination chemotherapy of breast cancer cells[J].J Biomater Sci Polym Ed,2021,32(5):657-677.
30 Chen H,Xing L,Guo H,et al.Dual-targeting SERS-encoded graphene oxide nanocarrier for intracellular co-delivery of doxorubicin and 9-aminoacridine with enhanced combination therapy[J].Analyst,2021,146(22):6893-6901.
31 Gharehdaghi Z,Rahimi R,Naghib SM,et al.Cu(II)-porphyrin metal-organic framework/graphene oxide:Synthesis,characterization,and application as a pH-responsive drug carrier for breast cancer treatment[J].JBIC J Biol Inorg Chem,2021,26:689-704.
32 Kurmi BD,Paliwal SR.Development and optimization of TPGS-based stealth liposome of doxorubicin using Box-Behnken design:characterization,hemocompatibility,and cytotoxicity evaluation in breast cancer cells[J].J Liposome Res,2022,32(2):129-145.
33 Darby RA,Callaghan R,McMahon RM.P-glycoprotein inhibition:the past,the present and the future[J].Curr Drug Metab,2011,12(8):722-731.
34 Yefimova SL,Kurilchenko IY,Tkacheva TN,et al.Comparative study of dye-loaded liposome accumulation in sensitive and resistant human breast cancer cells[J].Exp Oncol,2012,34(2):101-106.
35 Di H,Wu H,Gao Y,et al.Doxorubicin-and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy[J].Drug Dev Ind Pharm,2016,42(12):2038-2043.
36 Xu C,Xu J,Zheng Y,et al.Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer[J].J Mater Chem B,2020,8(13):2726-2737.
37 Jung H,Mok H.Mixed micelles for targeted and efficient doxorubicin delivery to Multidrug-Resistant breast cancer cells[J].Macromol Biosci,2016,16(5):748-758.
38 Guo S,Zhang X,Gan L,et al.Effect of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride:potential involvement of breast cancer resistance protein(ABCG2)[J].J Pharm Pharmacol,2010,62(8):973-984.
39 Agnello L,Tortorella S,d'Argenio A,et al.Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors[J].J Exp Clin Cancer Res,2021,40:1-17.
40 Banti CN,Raptopoulou CP,Psycharis V,et al.Novel silver glycinate conjugate with 3D polymeric intermolecular self-assembly architecture;an antiproliferative agent which induces apoptosis on human breast cancer cells[J].J Inorg Biochem,2021,216:111351.
41 Makvandi P,Chen M,Sartorius R,et al.Endocytosis of abiotic nanomaterials and nanobiovectors:Inhibition of membrane trafficking[J].Nano Today,2021,40:101279.
42 Ganji M,Dashtestani F,Neghab HK,et al.Gold nanoparticles conjugated L-lysine for improving cisplatin delivery to human breast cancer cells[J].Curr Drug Deliv,2021,18(6):753-760.
43 Zhou F,Feng B,Yu H,et al.Cisplatin prodrug-conjugated gold nanocluster for fluorescence imaging and targeted therapy of the breast cancer[J].Theranostics,2016,6(5):679.
44 Magalhaes M,Alvarez-Lorenzo C,Concheiro A,et al.RNAi-based therapeutics for lung cancer:biomarkers,microRNAs,and nanocarriers[J].Expert Opin Drug Deliv,2018,15(10):965-982.
45 Fu Z,Zhang X,Zhou X,et al.In vivo self-assembled small RNAs as a new generation of RNAi therapeutics[J].Cell Res,2021,31(6):631-648.
46 Kim MJ,Chang H,Nam G,et al.RNAi-based approaches for pancreatic cancer therapy[J].Pharmaceutics,2021,13(10):1638.
47 Kumar A,Singam A,Swaminathan G,et al.Combinatorial therapy using RNAi and curcumin nano-architectures regresses tumors in breast and colon cancer models[J].Nanoscale,2022,14(2):492-505.
48 Xin Y,Huang M,Guo W W,et al.Nano-based delivery of RNAi in cancer therapy[J].Mol Cancer,2017,16:1-9.
49 Taniguchi H,Natori Y,Miyagi Y,et al.Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/ nanocarrier complex[J].Int J Cancer,2021,149(3):646-656.
50 Maurer V,Altin S,Ag Seleci D,et al.In-vitro application of magnetic hybrid niosomes:targeted siRNA-delivery for enhanced breast cancer therapy[J].Pharmaceutics,2021,13(3):394.
51 Yang YY,Zhang W,Liu H,et al.Cell-penetrating peptide-modified graphene oxide nanoparticles loaded with rictor siRNA for the treatment of triple-negative breast cancer[J].Drug Des Devel Ther,2021,15:4961-4972.
52 Liang Z,Du L,Zhang E,et al.Targeted-delivery of siRNA via a polypeptide-modified liposome for the treatment of gp96 over-expressed breast cancer[J].Mater Sci Eng C,2021,121:111847.
53 Yuan Y,Li E,Zhao J,et al.Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer[J].Anti-Cancer Drugs,2021,32(2):178-188.

[1]	WANG Rui, MA Deyuan, JIA Wangqiang, GUAN Quanlin. Application and progress of nano-medicine mediated cuproptosis in the breast cancer treatment [J]. Journal of Practical Oncology, 2025, 39(2): 144-150.
[2]	WANG Ru, ZHANG Hongxia. Research progress on the application of magnetic resonance imaging technology in predicting lymphatic vascular invasion in breast cancer [J]. Journal of Practical Oncology, 2025, 39(2): 162-168.
[3]	GU Wen, ZHOU Lan, JIA Yanni, HUANG Weidong. Validation of measurement attributes for QLU-C10D scale in breast cancer patients [J]. Journal of Practical Oncology, 2025, 39(1): 49-55.
[4]	SHI Changyong, ZHOU Zizhen, ZHOU Guanglin, XIONG Yimin. The values of DCE-MRI quantitative parameters combined with NCAPH in the diagnosis of early breast cancer [J]. Journal of Practical Oncology, 2025, 39(1): 56-60.
[5]	ZHANG Yuqing, JING Jing, LIU Zhaoliang, AN Jing, AN Weiwei. The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer [J]. Journal of Practical Oncology, 2024, 38(5): 313-322.
[6]	YANG Minye, XIAN Tongcheng, LIU Jingjian, BIE Jun, WANG Jie, LUO Yi. The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics [J]. Journal of Practical Oncology, 2024, 38(5): 323-329.
[7]	LIU Dong, ZHANG Taijuan, DANG Jifeng. The research progress of inflammatory reaction driving breast cancer metastasis [J]. Journal of Practical Oncology, 2024, 38(5): 336-341.
[8]	LI Qianni, XU Lingyan, LI Jian, YAO Xuepei, LIU Meina. Trend analysis of a longitudinal evaluation for multidimensional treatment quality of breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 213-220.
[9]	GAO Guangqiang, WANG Falin, LI Juan, TIAN Hong, GUO Sijia, YU Xiaolan, YANG Tingting, LIU Jiaren. β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway [J]. Journal of Practical Oncology, 2024, 38(4): 254-261.
[10]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.
[11]	YIN Haiyan, CHUN Zhiming, MA Qiaojun, CHENG Han, DING Gaoheng, LIU Yuqin, ZHANG Haiyan. Epidemic characteristics of female breast cancer in cancer registration areas of Gansu province in 2019 and trend analysis from 2010 to 2019 [J]. Journal of Practical Oncology, 2024, 38(3): 141-148.
[12]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[13]	MENG Fangang, CHEN Fei, ZHEN Lijun. Effects of DLX2 on proliferation,migration,invasion,apoptosis of breast cancer cells and characteristics of breast cancer stem cells [J]. Journal of Practical Oncology, 2024, 38(2): 88-95.
[14]	ZHENG Pengfei, DONG Liangpeng, GAO Yanxin, ZHANG Yifu, QIN Shuang. Effect of interleukin-38 to CD8⁺T lymphocyte function in patients with breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 30-36.
[15]	XIE Junling. Research progress of activated leukocyte adhesion molecule in breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 45-49.

Advances in the application of nanoparticles in the diagnosis and treatment of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments